2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02166944 (ClinicalTrials.gov)	April 2014	9/6/2014	Tamoxifen Treatment in Patients With Motor Neuron Disease	The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease	Amyotrophic Lateral Sclerosis;ALS Functional Ration Scale;TAR-DNA-binding Protein-43;Tamoxifen;mTOR	Drug: tamoxifen 40 mg daily for one year	Taipei Medical University Shuang Ho Hospital	NULL	Completed	20 Years	80 Years	All	20	Phase 1/Phase 2	Taiwan
2	NCT01257581 (ClinicalTrials.gov)	March 2011	8/12/2010	Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: creatine;Drug: tamoxifen	Nazem Atassi	ALS Therapy Alliance;State University of New York - Upstate Medical University	Completed	18 Years	N/A	All	60	Phase 2	United States
3	NCT00214110 (ClinicalTrials.gov)	January 2001	13/9/2005	Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]	Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]	Amyotrophic Lateral Sclerosis (ALS)	Drug: Tamoxifen	University of Wisconsin, Madison	NULL	Completed	18 Years	90 Years	Both	100	Phase 2	United States